High Throughput Flow Assay Trends 2017
|出版日期||內容資訊||英文 59 Pages
This market report summarizes the results of HTStec's industry-wide global web-based benchmarking survey on high throughput flow cytometry (HT flow) screening carried out in January 2017.
The survey was initiated by HTStec as part of its tracking of emerging life science marketplaces and to update HTStec's previous HT Flow Assay Trends report (January 2015).
The questionnaire was compiled to meet the needs, requirements and interests of the flow cytometry vendor community.
The objectives were to document the current implementation and use of HT flow assays in screening, and to understand future user requirements. The aim was to compile a reference document on HT flow assays, which could be compared directly relative to our previous 2015 report.
Equal emphasis was given to soliciting opinion from the large molecule, small molecule and immunoassay screening segments worldwide.
The survey looked at the following aspects of HT flow screening, as practiced today (2017) and in a few cases as predicted for the future (2019): why respondents have enabled or why they are interested in HT flow; how respondents have achieved HT flow analysis to date and typical throughput realised with current instrument approach; will implementation of HT flow mainly displace or complement existing screening technologies; key diseases/therapeutic areas targeted with HT flow screening; target classes most interested in applying HT flow assays; broad applications areas most using or most considering using HT flow assays; key applications for HT flow in respondent's research; main benefits of HT flow versus other techniques; plate processing time considered adequate for HT flow needs; preferred sample presentation/handling format for HT flow and the target sample (aspirate) volume; number of parameters to be multiplexed in cell-based HT flow assays; number of analytes to be multiplexed in bead-based HT flow assays; samples types to be analysed with HT flow; where cell markers of interest in HT flow screens are located; main cell labelling technique/source; type of endpoints of most interest in HT flow screens; intention to carry out any front end processing or sample preparation prior to HT flow; number of different primary screens and number of wells to be tested per screen for cell-based and bead-based HT flow assays; estimated cost per sample (microplate well) analysed using cell-based and bead-based HT flow assays; vendor that first comes to mind when thinking of flow cytometry in general and HT flow specifically; plans to purchase any instrumentation to enable HT flow assays; capex budget for HT flow detection instruments; reagents and consumables budget for HT flow assays; how respondents have deployed HT flow instrumentation into their screening environment/core facility; biggest limitations (obstacles) in using HT flow assays today; ratings of possible limitations of HT flow; biggest hurdles in software and data analysis for HT flow; level of agreement with statements about the status of HT flow assays; and any unmet needs in HT flow screening today.
The main questionnaire consisted of 28 multi-choice questions and 3 open-ended questions. In addition, there were 6 questions related solely to the administration of the survey or demographics.
The survey collected 75 validated responses, of these 77% provided comprehensive input.
Survey responses were geographically split: 57% North America; 27% Europe; 7% Asia (excluding Japan & China); 5% Rest of World; and 4% Japan.
Survey respondents were drawn from persons or groups undertaking HT flow screening or those contemplating future investigation in the area.
Respondents represented 26 University/Research Institute/Government Lab/Not-For-Profit; 17 Biotech Company; 16 Large Pharma; 6 Medium-Small Pharma; 5 Biopharma; 2 Academic Screening Center; 2 Contract Research Organisation; and 1 Medical School/Hospital/Clinic.
Most survey respondents had a senior job role or position which was in descending order: 28 research scientists; 10 senior scientists/researchers; 8 lab managers; 6 directors; 5 principal investigators; 4 post-docs; 4 section/group leaders; 3 graduate/PhD students; 3 professors/assistant professors; 3 other roles; and 1 department head.
Survey results were expressed as an average of all survey respondents. In addition, where appropriate the data was reanalysed after sub-division into the following 5 survey groups: 1) Large Molecule Screening; 2) Small Molecule Screening; 3) Immunoassay Screening; 4) Using; and 5) Not Yet Using.
Feedback on why respondents have enabled or why they are interested in HT flow was documented.
The majority of respondents were using HT flow assays in screening today, the remainder aspire to or intend to implement in the near future.
HT flow analysis has been most achieved to date by using a flow cytometer with sample acquisition enabled direct from microplate wells.
The median throughput realised to date by current approaches to HT flow was 500-1K samples/day.
The majority of respondents believe implementing HT flow will complement existing technologies.
The majority of respondents were targeting HT flow assays within the oncology/cancer disease area.
Respondents rated they were most interested in applying HT flow assays to membrane receptor targets.
The use or planned use of HT flow assays was split relatively evenly between large molecule screening, small molecule screening and immunoassay screening.
Immunoassays were selected as the key application area of HT flow in respondent's research.
Ability to analyse multiple cell populations within each microplate well was ranked the greatest benefit (advantage) of HT flow versus other techniques.
The median requirements for HT flow sampling and analysis in a 96-well plate sample presentation/ handling format were: 10 min plate processing time; 5-10μL sample (aspirate) volume; 5-7 parameters multiplexed in cell-based assays; and 8-10 analytes multiplexed in bead-based assays.
The samples types most want to analyse by HT flow assays were cultured suspension cell lines for whole population studies and human blood samples for sub-population studies.
Cell markers of interest in HT flow screens were mainly located on the cell surface.
Commercial antibodies were rated the main labelling technique/source used for HT flow assays.
The type of endpoints of most interest were a mix of both functional and immunophenotypic endpoints.
Most respondents undertake sample prep to improve the detection of all cells prior to HT flow assay.
A median of 5 primary cell-based screens (HTS) each with 1K to 5K wells were run by HT flow today.
A median of 1 primary bead-based screens (HTS) each with <1K wells were run by HT flow today.
The median cost paid/sample analysed using cell-based HT flow assays today was $0.25-$0.5/well.
The median cost paid/sample analysed using bead-based HT flow assays today was $0.25-$0.5/well.
The vendor that first comes to mind for flow cytometry in general was BD Biosciences.
The vendor that first comes to mind for HT flow was Intellicyt.
Only a minority of respondent have purchased instruments enabling HT flow screening in 2016.
The median purchasing probability over the next few years (up to 2019) was possible (26-50%).
The preferred vendors for new HT flow instrumentation purchasing were Intellicyt and BD Biosciences.
The median capex annual budget for HT flow detection instruments was $150K-$200K.
The global market for HT flow detection instruments was estimated to be around $40M in 2016.
The median annual budget for reagents and consumables for HT flow assays was $25K-$50K.
The global market for HT flow reagents and consumables was estimated to be around $70M in 2016.
The main deployment of HT flow instrumentation into a screening environment/core facility was as part of a semi-automated setup e.g. with some additional peripheral automation and liquid handling.
Feedback on the biggest limitations in using HT flow assays were documented.
Investment in additional expensive instrumentation was rated as the main limitation of HT flow assays.
Interpreting complex multi-parametric data was ranked the biggest hurdle in software and data analysis for HT flow assays.
The level of agreement with some statements about the status of HT flow assays was most positive (had greatest agreement) with ‘HT flow is the ideal high content platform for phenotypic screening'; and most negative (had greatest disagreement) with ‘HT flow is nothing more than a prescreen for more sophisticated imaging-based analyses'.
Some feedback on any unmet needs in HT flow assays today were documented.
The full report provides the data, details of the breakdown of the responses to each question, its segmentation and estimates for the future (2019). It also highlights some interesting differences between the survey groups.
For the purpose of this report HT flow assays were defined as those that utilize automated sampling methods to transfer from a microplate, multiparameter and/or multiplexed assay components suspended in solution (including cells, beads, yeast and bacteria) to the flow cytometer detection system in a continuous stream.